RTX is more effective than AZA for maintenance of remission, but GC use and relapse remain common^6-9

• RTX was shown to be a more effective maintenance therapy than AZA for newly diagnosed AAV patients
• Minor and major relapses occurred throughout the maintenance phase of treatment. By Month 28, 17% of patients suffered a major relapse, increasing to 38% by Month 60
• GC use remained common amongst all patients throughout the 60-month follow-up period